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0883-9441/© 2018 Elsevier Inc. All rights reserved.a b s t r a c ta r t i c l e i n f oKeywords: Background: The aim of this proof of concept, prospective, randomized pilot trial was to investigate the effects of
extracorporeal cytokine removal (CytoSorb®) applied as a standalone treatment in patients with septic shock.
Methods: 20 patients with early (b24 h) onset of septic shock of medical origin, on mechanical ventilation,
norepinephrineN10 μg/min, procalcitonin (PCT) N 3 ng/mL without the need for renal replacement therapy
were randomized into CytoSorb (n=10) and Control groups (n= 10). CytoSorb therapy lasted for 24 h. Clinical
and laboratory data were recorded at baseline (T0), T12, T24, and T48 hours.
Results: Overall SOFA scores did not differ between the groups. In the CytoSorb-group norepinephrine require-
ments and PCT concentration decreased signiﬁcantly (norepinephrine: CytoSorb: T0 = 0.54[IQR:0.20–1.22],
T48 = 0.16[IQR:0.07–0.48], p= .016; Controls: T0 = 0.43[IQR:0.19–0.64], T48 = 0.25[IQR:0.08–0.65] μg/kg/min;
PCT: CytoSorb: T0 median = 20.6[IQR: 6.5–144.5], T48 = 5.6[1.9–54.4], p= .004; Control: T0 = 13.2[7.6–47.8],
T48 = 9.2[3.8–44.2]ng/mL). Big-endothelin-1 concentrations were also signiﬁcantly lower in the CytoSorb
group (CytoSorb: T0 = 1.3 ± 0.6, *T24 = 1.0 ± 0.4, T48 = 1.4 ± 0.8, *p= .003; Control: T0 = 1.1 ± 0.7, T24 =
1.1 ± 0.6, T48 = 1.2 ± 0.6 pmol/L, p= .115). There were no CytoSorb therapy-related adverse events.
Conclusions: This is theﬁrst trial to investigate the effects of early extracorporeal cytokine adsorption treatment in
septic shock applied without renal replacement therapy. It was found to be safe with signiﬁcant effects on nor-
epinephrine requirements, PCT and Big-endothelin-1 concentrations compared to controls.
Trial registration: The study has been registered on ClinicalTrials.gov, under the registration number of
NCT02288975, registered 13 November 2014.
© 2018 Elsevier Inc. All rights reserved.Septic shock
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Sepsis and septic shock is a devastating condition with mortality
rates between 20 and 50% [1-3]. The pathophysiology of sepsis is
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ginswith the host's immune response triggered by various insults [6]. In
sepsis, this response to an infectious insult becomes dysregulated, and
cytokines, chemokines and other inﬂammatory regulators are released
leading to an imbalance between the pro-, and anti-inﬂammatory
forces. This condition is also referred to as a ‘cytokine storm’ [7]. The
hypothesis that a cytokine storm may be responsible for the observed
self-destructive sequence of events in sepsis forms the pathophysiolog-
ical rationale of mass removal of circulating cytokines [8,9].
When basic therapeutic measures, such as early adequate resuscita-
tion, source control and organ support fail to improve the patients'
condition, additional therapeutic alternatives, called ‘adjuvant thera-
pies’, are sometimes considered in order to improve outcome [9]. The
most frequently investigated adjuvant therapies are: immunoglobulin-
therapy, endotoxin-binding Polymyxin B hemoperfusion, and
high-capacity continuous blood-, and plasma ﬁltration [10-12]. One of
the recent adjuvant alternatives is extracorporeal cytokine adsorption
with a device called CytoSorb® (CytoSorbents Corporation, New Jersey,
USA) that became available in clinical practice in 2011. This is a high-
173F. Hawchar et al. / Journal of Critical Care 49 (2019) 172–178ﬂow, low-resistance cytokine adsorbent, containing specially developed
polymer beadswith a huge adsorption surface and adsorption spectrum
between 5 and 60 kDa [13].
There are over 100 case studies that describe the use of extracorpo-
real cytokine adsorption in many clinical scenarios, and in general, the
effects are promising and the treatment well tolerated. With regard to
the treatment of sepsis, clinical trials are lacking at present, and what
we have are mainly small case series [14-17]. There is also an interna-
tional CytoSorb Registry, and recent data analysis on 198 patients indi-
cate that observedmortality (65%)was substantially better compared to
predicted (mean of 81%), and treatment was also shown to be safe [18].
However, the treatment has mainly been used together with renal
replacement therapy and no study has tested its effect when applied
as an adjuvant therapy on its own.
Therefore, the aim of this prospective, randomized, controlled, proof
of concept (i.e.: testing it as a standalone extracorporeal treatment without
the need of renal replacement therapy), pilot study was to investigate the
effects of early (started within 24 h after ICU administration), 24-h long
cytokine-adsorption therapy on organ dysfunction and inﬂammatory
response in patients with septic shock, and to provide further data on
safety.
2. Materials and methods
2.1. Patients
All patients with septic shock of medical origin were screened for
suitability for the study from January 2015 to December 2017 on a
level III, 36 bedded multidisciplinary intensive care unit (ICU) in our
university hospital. The inclusion and exclusion criteria were the
following.
Inclusion criteria: Intubated, mechanically ventilated patients with
suspected septic shock of medical origin; invasive hemodynamic moni-
toring guided demand for norepinephrine N10 μg/min; elevated lactate
concentrations N2.0 mmol/L; and a procalcitonin (PCT) concentration
≥ 3 ng/mL were considered candidates for the study. Inclusion had to
take place after the ﬁrst 6 h at least of resuscitation and antibiotic
therapy, when there was no improvement as indicated by steady or in-
creased norepinephrine requirements, and study treatment should be
commenced within the ﬁrst 24 h after ICU admission or the onset of
septic shock.
2.2. Exclusion criteria
Patients under 18 years of age; acute or chronic renal insufﬁciency
requiring renal replacement therapy; pregnancy (β-hCG test positiv-
ity); operation in connection with the septic condition of the patient;
end-stage cardiomyopathy; acute coronary syndrome; cardiogenic
shock; hemato-oncological diseases; admission after cardiac arrest;
immune-compromised patients due to HIV positivity and active AIDS
or organ transplantation or on chronic steroid treatment (N10 mg/day
prednisolone); thrombocytopenia (b20 G/L); other coagulopathies
contraindicating extracorporeal therapies.
3. Randomization and interventions
Patients who fulﬁlled the entry criteria were randomized into
CytoSorb or Control groups by sealed envelope block randomization
(blocks of 10). Randomized envelopes were numbered and were opened
one by one when including a patient. Random allocation sequence was cre-
ated by IL. Randomization and patient enrolment was performed by FH, IL,
NÖ and DT. Patients in both groups received standard treatment accord-
ing to the institutional adaptation of the Surviving Sepsis Guidelines
[19]. In addition to routinemonitoring (such as 5‑lead ECG, pulse oxim-
etry, invasive arterial blood pressure measurement, hourly diuresis,
temperature, end-tidal CO2, airway pressures, etc.), invasivehemodynamic monitoring by using the PiCCO technology (PiCCO,
PULSION-Maquet, Germany) was also applied and hemodynamic
management was guided accordingly. The main parameters assessed
were: cardiac index (CI), pulse pressure variation (PPV), systemic vascular
resistance index (SVRI) and extravascular lung water index (ELWI).
Patients in the CytoSorb group received a hemodialysis catheter
inserted into a central vein (femoral, subclavian or internal jugular, as
appropriate). Treatment was performed as instructed by the company's
user guide. In short, CytoSorbwas placed in a blood pump circuit using a
renal replacement device (MultiFiltrate, Fresenius Medical Care, Bad
Homburg von der Höhe, Germany), with heparin anticoagulation and
a blood ﬂow rate of 250–400 mL/min.4. Measurements
First measurements (T0) were performed right after inclusion
(Control group) or after the start of extracorporeal cytokine adsorption
therapy, then 12, 24 and 48 h later (T12, T24, T48). At these time points
blood sampleswere drawn and complete hemodynamicmeasurements
as well as arterial and central venous blood gas analysis and determina-
tion of inﬂammation marker concentrations were performed. Serum
PCT, CRP and bigendothelin-1 (BigET-1) were determined by the
hospital's central laboratory. Sequential (Sepsis-related) Organ Failure
Assessment (SOFA) scores were calculated to monitor organ dysfunc-
tion [20].5. Safety
Potentially, complications may be similar to that of any extracorpo-
real technique: related to central vein cannulation or bleeding due to
anticoagulation, but the extracorporeal cytokine adsorption therapy it-
self may also provoke an unexpected allergic response, or other effects
which may affect organ function. In order to assess safety, regular anal-
ysis of clotting, and organ function were assessed.6. Statistical analysis
As this was meant to be a proof of concept pilot study, investigating
the safety andpotential clinical effects of the treatment, the original idea
was to include 20 patients (10 in each group). Power calculation was
not performed due to the lack of similarly designed studies in the liter-
ature at the timewhen the study protocolwaswritten. In fact, the aimof
this study was to provide data for power calculations for future studies
(hence the proof of concept, pilot fashion), to investigate certain clinical
effects as the primary outcome but not mortality, as the latter would
have required far higher patient numbers.
Data were primarily recorded in Microsoft Excel 2016. Data were
analyzed using IBM SPSS 23.0 (Armonk, NY, USA) and Systat Software
Inc. SigmaPlot 12.5 (London, UK). Shapiro-Wilk test was used to test
normality. In case of demographic data, Student t-test or Mann-
Whitney U test was applied. Analysis of variance (ANOVA) with
Bonferroni post hoc test was used to compare the groups. The level of
signiﬁcance was deﬁned as p b .05.7. Results
Patients were included between January 2015 until December 2017.
All patients with suspected septic shock were screened for eligibility
(Fig. 1). From the relatives of those who fulﬁlled the inclusion criteria
written informed consent was obtained before the study. In 3 cases
we could not obtain consent, hence we extended the study to recruit
3 more patients (hence the total of 23) to reach the target of 10 per
group.
Fig. 1. Flowchart of patient screening and involvement according to CONSORT.
174 F. Hawchar et al. / Journal of Critical Care 49 (2019) 172–1787.1. Demography
Patients' demographic data are summarized in Table 1. Therewas no
signiﬁcant difference between CytoSorb and Control groups regarding
age, body mass index, days spent on the ICU and APACHE II scores. All
patients survived the ﬁrst day of the study. All patients survived the
study period of 48 h in the CytoSorb group, but 2 patients died in the
Control group just before the 48th hour time period, hence in these 2
cases the last availablemeasurementswere used for analysis, otherwise
ICU mortality was similar.
7.2. SOFA scores
The SOFA scores in the CytoSorb group (T0= 13.6± 3.2; T12= 13.1
±3.6; T24=13±5.4; T48=11.6±6.3) did not differ signiﬁcantly from
the Control group (T0=12.8± 3.9; T12= 12.9± 5.0; T24= 12.6± 5.9;
T48 = 11.0 ± 6.3).
7.3. Hemodynamic parameters
Results of the hemodynamic measurements are shown in Table 2.
There were no signiﬁcant differences either within, or between the
groups as far as mean arterial pressure (MAP), heart rate (HR), cardiac
index (CI) and pulse pressure variability (PPV) were concerned.Table 1
Demographic data.
Parameters All
N (male/female) 20 (13/7)
Age (years) 65.6 ± 12.9
Body Mass Index 28.8 ± 8.0
ICU length of stay (days) 10.1 ± 6.5
APACHE II 28 ± 7
Mortality within 48 h 2
Etiology (n) –
Number of dialysis treatments 47
N: number of subjects, ICU: Intensive Care Unit, APACHE II: Acute Physiology and Chronic HeaExtravascular lung water index (ELWI) was higher in the CytoSorb
group and showed decreasing tendencies in both groups, but these
differences did not reach statistical signiﬁcance. Systemic vascular resis-
tance (SVRI) decreased gradually in the Control group until T24, while it
showed an increasing tendency in the CytoSorb group during treat-
ment, although this did not prove to be signiﬁcant. Patients in the
CytoSorb group required almost twice the norepinephrine dose on
entering the study as Controls, a difference that was not signiﬁcant,
but there was a signiﬁcant decrease in this group (by almost 70% com-
pared to baseline), which was not observed in the Control group
(Fig. 2). Patients received similar amount of ﬂuid replacement over
the study period.7.4. Blood gas parameters
Lactate concentrations were elevated initially and decreased in both
groups (Table 2). Central venous to arterial CO2-gap (pCO2-gap)
changed in opposite directions: decreasing in the CytoSorb and increas-
ing in the Control group, but these changes did not achieve statistical
signiﬁcance. Similar values of ScvO2 were observed in both groups.
Oxygenation, as indicated by PaO2/FiO2, were lower in the CytoSorb
group and showed improvement by T48, which remained more or less
unchanged in the Control group, although these changes remained
non-signiﬁcant.CytoSorb Control
10 (7/3) 10 (6/4)
60 ± 10 71 ± 14
30.5 ± 10.2 26.9 ± 4.4
10.2 ± 8.5 10.0 ± 4.3
26 ± 9 30 ± 6
0 2
Pneumonia (7)
pancreatitis (1)
toxic shock syndrome (1)
urosepsis (1)
Pneumonia (6)
meningococcus sepsis (2)
cholangiosepsis (1)
dermatomyositis (1)
2.6 ± 1.5 2.1 ± 4.3
lth Evaluation II score. Data are presented as mean ± standard deviation.
Table 2
Hemodynamic and laboratory parameters.
Group T0 T12 T24 T48
MAP (mmHg) CytoSorb 80 ± 10 74 ± 9 76 ± 9 81 ± 15
Control 83 ± 8 82 ± 8 79 ± 10 84 ± 10
HR (1/min) CytoSorb 69 ± 12 69 ± 26 73 ± 28 59 ± 14
Control 62 ± 13 76 ± 24 67 ± 12 71 ± 12
CI (l/min/m2) CytoSorb 3.2 ± 1.1 3.1 ± 1.2 3.2 ± 1.5 3.4 ± 1.1
Control 3.0 ± 0.8 3.8 ± 0.5 3.8 ± 0.7 3.5 ± 0.9
PPV (%) CytoSorb 12.2 ± 5.3 14.9 ± 6.1 12.1 ± 6.2 12.6 ± 5.6
Control 11.8 ± 5.7 13.9 ± 7.4 12.1 ± 6.9 13.7 ± 4.9
EVLWI (mL/kg) CytoSorb 16.4 ± 10.1 14.6 ± 6.0 13.6 ± 6.1 13.1 ± 5.0
Control 8.7 ± 3.7 7.8 ± 2.5 7.8 ± 3.0 7.1 ± 1.7
SVRI
(dyn × s/cm5/m2)
CytoSorb 1909 ± 497 2030 ± 755 1946 ± 598 1806 ± 494
Control 2314 ± 812 1656 ± 252 1588 ± 300 1852 ± 377
Cumulative total i.v. ﬂuid (mL) CytoSorb – 2195.8 ± 1319.0 3922.1 ± 1634.2 6861.6 ± 1488.3
Control – 2370.3 ± 816.6 4639.2 ± 2477.1 7648.3 ± 2988.3
Lactate (mmol/L) CytoSorb 3.6 ± 3.9 4.4 ± 4.7 3.1 ± 3.3 2.4 ± 2.9
Control 3.0 ± 2.4 2.1 ± 1.2 1.6 ± 0.7 1.4 ± 0.5
CO2 gap (mmHg) CytoSorb 7.8 ± 3.5 7.0 ± 3.4 6.1 ± 3.6 4.1 ± 4.7
Control 2.8 ± 5.4 4.8 ± 2.8 4.7 ± 1.8 6.6 ± 1.6
ScvO2 (%) CytoSorb 75.8 ± 9.6 78.4 ± 8.2 76.3 ± 5.4 77.9 ± 5.0
Control 80.9 ± 5.7 82.1 ± 4.2 81.1 ± 3.5 78.2 ± 6.0
PaO2 /FiO2
(mmHg)
CytoSorb 173.2 ± 64.2 212.7 ± 99.2 293.9 ± 207.1 243.9 ± 116.8
Control 249.5 ± 127.6 215.5 ± 81.0 227.5 ± 100.4 244.0 ± 83.0
CRP (mg/L) CytoSorb 238.1 ± 95.5 226.8 ± 109.2 220.3 ± 104.0 169.54 ± 86.4
Control 307.4 ± 116.7 307.7 ± 104.2 280.4 ± 80.8 189.9 ± 48.5
BigET-1 (pmol/L) CytoSorb 1.3 ± 0.6 0.9 ± 0.3# 1.0 ± 0.4# 1.4 ± 0.8
Control 1.1 ± 0.7 1.0 ± 0.5 1.1 ± 0.6 1.2 ± 0.6
eGFR (mL/min/m2) CytoSorb 31.0 ± 19.4 30.0 ± 14.9 35.3 ± 19.5 34.0 ± 21.6
Control 41.3 ± 15.7 40.6 ± 19.2 44.9 ± 25.6 45.4 ± 26.3
Creatinine (μmol/L) CytoSorb 215.7 ± 187.5 181.5 ± 124.6 164.3 ± 123.68 177.1 ± 166.0
Control 141.4 ± 87.9 181.8 ± 105.1 186.3 ± 158.7 147.6 ± 138.8
Fluid balance (mL/24 h) CytoSorb – 1454.7 ± 1382.2 1089.6 ± 861.1 1475.1 ± 1262.7
Control – 1210.2 ± 940.8 1239.1 ± 1829.6 1166.7 ± 1258.3
MAP: mean arterial pressure, HR: heart rate, CI: cardiac index, PPV: pulse pressure variation, EVLWI: extravascular lungwater index, SVRI: systemic vascular resistance index, ScvO2: cen-
tral venous oxygen saturation, PaO2: partial arterial oxygen pressure, FiO2: fraction of inspired oxygen, CRP: C-reactive protein, BigET-1: big endothelin-1. Data are presented as mean ±
standard deviation; #: p b .05 vs.T0.
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Regarding CRP concentration, the CytoSorb and Control groups did
not differ signiﬁcantly and both groups showed a decrease by T48
(Table 2).
Regarding PCT (Fig. 3), there was a signiﬁcant decrease in both
groups, however, the kinetics were different. In the Control group, aFig. 2. Kinetics of norepinephrine need in the CytoSorb and in the Control group. Data are
shown as median and interquartile ranges. *p b .05 vs. T0.signiﬁcant drop in PCT was detected at T48 (p = .04 vs. T0), while in
the CytoSorb group this decrease was more pronounced and was al-
ready signiﬁcant at T24 and also at T48.Fig. 3. Procalcitonin kinetics in the CytoSorb and in the Control group. Data are presented
as median and interquartile ranges. *p b .05 vs. T0CytoSorb, #p b .05 vs. T0Control.
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and T24 as compared to baseline, and remained almost unchanged in
the Control group (Table 2).
7.6. Adverse effects
Finally, we did not observe any adverse effects due to extracorporeal
cytokine adsorption therapy.
8. Discussion
This proof of concept pilot study found that adjunctive therapy with
standalone extracorporeal cytokine removal for 24 h during the early
phase of therapy-resistant septic shock proved to be safe and also re-
sulted some signiﬁcant effects compared to the control group.
8.1. Clinical effects
In the current study, we did not observe any intervention related
adverse events, hence 24-h adsorption therapy proved to be safe
which is in accordwith previously reported case series and clinical stud-
ies [21-24].
Though there were no signiﬁcant differences in the SOFA scores
between the groups at T24, but this may be a too robust outcome mea-
sure within such a short period of time and longer term improvements
in overall organ function may require a series of treatments. Regarding
the length and number of treatments and indicators for terminating ex-
tracorporeal cytokine adsorption therapy are very important questions
to be answered in the future.
Mortalitywas 50% in both groups, however itwasn't the aim to show
the effect of one single treatment on survival. Nevertheless, it may be
important to note, that although patients looked more severe in the
CytoSorb group, they all survived the 48 h of the study, while 2 patients
died in the Control arm before reaching the 48 h.
One of the most important effects of extracorporeal cytokine
removal treatment observed in the current studywas the signiﬁcant re-
duction in the need for vasopressor support, while in the Control group
this change could was not shown. This ﬁnding was also supported by
the measured SVRI values. Although the difference between the groups
did not reach statistical signiﬁcance, these results at least provide some
physiological background that vasodilatation, most likely due to the
overwhelming effects of pro-inﬂammatory cytokines, was better con-
trolled in the treated group. This ﬁnding is in accordance with previ-
ously reported data, both in case series and in recent clinical studies
[25]. It is also important to note, that themost profound effectswere ob-
served during the ﬁrst 12 h of treatment, which has not been reported
before.
8.2. Effects on biomarkers
There is a broad array of cytokines and biomarkers that can be mea-
sured. However, in clinical practice there are only one or two that are
used routinely. Our choices were PCT and CRP, as these are measured
in our everyday practice.
The adsorption spectrum of the capsule is between 5 and 60 kDa
[13]. Besides the reduction in vasopressor requirement, the most signif-
icant effect of cytokine adsorption therapy compared to Controlswas on
PCT concentrations. Procalcitonin has a molecular weight of 13 kDa,
hence CytoSorb may adsorb PCT directly. Indeed, as hypothesized, in
the treatment group there was a signiﬁcant decrease in PCT concentra-
tions during the ﬁrst 24 h,whichwas not observed in the Control group.
By T48 PCT decreased signiﬁcantly in both groups, a pattern that has
been observed in several studies when standard treatment is effective
[26]. In a previous pilot study, where we measured PCT simultaneously
before and after the cartridge, we reported that PCT is directly adsorbed
by CytoSorb, and the adsorption is most effective during the ﬁrst 12 h oftreatment [27]. This explains why the PCT decrease was more
pronounced in the CytoSorb group in the current study. This may also
explain in part, why the norepinephrine requirement was reduced
within the same time frame of 12 h after the commencement of extra-
corporeal cytokine adsorption therapy. These results suggest, that
changing the adsorber after 12 h may prove to be beneﬁcial, but this
should be tested in the future. This is further supported by the ﬁnding,
that after the discontinuation of extracorporeal cytokine adsorption
therapy, PCT and norepinephrine tended to increase, although this
change was not signiﬁcant. These results also suggest, that the PCT
kinetics that we have previously described to predict antibiotic appro-
priateness [30], cannot be applied during extracorporeal cytokine ad-
sorption treatment.
Nevertheless, the pathophysiological role of PCT in sepsis is not yet
fully elucidated. PCT may be an important biomarker that indicates cy-
tokine storm [28], but may also be a toxic mediator in sepsis [29]. The
results of this experimental study found that pre-treating animals
with anti-PCT antigens, before infecting them with E-coli, improved
mortality dramatically while all untreated animals died [29]. In the cur-
rent study the decreasing PCT concentration was associated with im-
proved clinical parameters such as lower vasopressor need and
improved oxygenation. This is in accordancewith our previousﬁndings,
that PCT kinetics signiﬁcantly, andwithin amatter of 12–24 h, separated
patients who received appropriate antibiotics compared to those who
were administered inappropriate antibiotics, which was also reﬂected
in better clinical outcomes [26].
This observation of signiﬁcantly reduced PCT concentrations some-
what contradict the results of a recently published clinical trial on extra-
corporeal cytokine adsorption therapy, in which the primary outcome
was change in normalized IL- 6-serum concentrations during study
days 1 and 7, but which found no signiﬁcant difference compared to
controls [30]. However, in this study the authors used a different ap-
proach (6-h treatment daily), the patient population was also different,
and they did not report on PCT concentrations or on norepinephrine
requirements.
Extracorporeal cytokine adsorption therapy did not inﬂuence CRP
concentration in our study. One of the reasons could be that although
CRP as amonomer has amolecularweight of around 25 kDa, it is usually
present as a pentamer, hence cannot be adsorbed by CytoSorb as
efﬁciently as PCT. Furthermore, since CRP has a relatively long half-life
and follows the inﬂammatory process with about 48 h delay, its use in
monitoring the disease progress or treatment efﬁcacywithin a short pe-
riod of time (12–24 h) may be limited [31].
In our study the natural precursor of endothelin-1, BigET-1
(4.2 kDa), decreased signiﬁcantly in the CytoSorb group between T0
and T12, T24. Previously BigET-1 was found to be markedly elevated in
patients with severe sepsis compared to healthy volunteers, and its
higher concentrations were in correlation with increased serum IL-6,
IL-8 concentration and renal failure [32]. Our results are in accordance
with these ﬁndings and hypothesize that there may be a link between
the observed reduced BigET-1 concentrations and the higher SVRI and
reduced norepinephrine requirement. Nevertheless, this should be in-
vestigated further.
8.3. Limitations
This study has several limitations. First of all, the sample size is far
too small to draw any ﬁrm conclusions regarding treatment effect on
organ function or outcome. Furthermore, our ﬁndingsmay not be general-
izable to other institutions with different patient populations or clinical
practices, and do not provide any data on long term adverse events (i.e.:
safety) and outcome. Power analysis was not performed due to the lack
of similarly designed studies with such strict criteria set to obtain a rel-
atively homogenous group of patients. By reason of the diversity of
septic shock patients, it took us N2 years to include 20 out of 716
screened subjects. Furthermore, despite all efforts heterogeneity was
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tions and patients seemed to be sicker in the CytoSorb group.
It would have been desirable to measure an array of cytokines, pref-
erably before and after the adsorber, but due to technical difﬁculties and
ﬁnancial limitations this could not be achieved.
9. Conclusions
To our best knowledge, this is the ﬁrst study, in which extracorpo-
real cytokine adsorption treatmentwas tested on its own, and not com-
bined with other extracorporeal renal replacement therapies in a
controlled trial. In this proof of concept pilot study, extracorporeal cyto-
kine removal was applied for 24 h in the early stage of septic shock. The
treatment proved to be safe, and we also found that one single
treatment already showed some beneﬁts as indicated by reductions in
norepinephrine requirements, serum PCT and BigET-1 compared to
Controls. These results may provide important support and guidance
to future protocol designs and can help to deﬁne the appropriate
study end points and sample size calculations of clinical trials that aim
to investigate the effects of cytokine removal in patients with septic
shock.
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